INSMED INC Paid-in-Kind Interest
INSMED INC (INSM) reported Paid-in-Kind Interest of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-02-19
- INSMED INC paid-in-kind interest for the quarter ending 2025-12-31 was $0.00.
- INSMED INC paid-in-kind interest for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC paid-in-kind interest for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC paid-in-kind interest for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC paid-in-kind interest for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- INSMED INC paid-in-kind interest for fiscal 2024 was $19.23M, a 17.71% decline from fiscal 2023.
- INSMED INC paid-in-kind interest for fiscal 2023 was $23.37M, a 461.15% increase from fiscal 2022.
- INSMED INC paid-in-kind interest for fiscal 2022 was $4.17M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $6.66M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $6.66M derived: sum of 3 quarters · filed 2026-02-19 | $12.99M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $6.66M derived: sum of 2 quarters · filed 2026-02-19 | $12.99M derived: sum of 3 quarters · filed 2026-02-19 | $19.23M 10-K · filed 2026-02-19 |
| 2024-09-30 | $6.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $12.99M derived: sum of 2 quarters · filed 2025-10-30 | $19.23M 10-Q · filed 2025-10-30 | $25.40M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $6.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.57M 10-Q · filed 2025-08-07 | $18.74M derived: sum of 3 quarters · filed 2026-02-19 | $24.74M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $6.24M 10-Q · filed 2025-05-08 | $12.41M derived: sum of 2 quarters · filed 2026-02-19 | $18.41M derived: sum of 3 quarters · filed 2026-02-19 | $24.16M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $12.17M derived: sum of 2 quarters · filed 2026-02-19 | $17.92M derived: sum of 3 quarters · filed 2026-02-19 | $23.37M 10-K · filed 2026-02-19 |
| 2023-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $11.75M derived: sum of 2 quarters · filed 2024-10-31 | $17.20M 10-Q · filed 2024-10-31 | $21.37M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $11.20M 10-Q · filed 2024-08-08 | $15.37M derived: sum of 3 quarters · filed 2025-02-20 | $15.37M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $5.46M 10-Q · filed 2024-05-09 | $9.62M derived: sum of 2 quarters · filed 2025-02-20 | $9.62M derived: sum of 3 quarters · filed 2025-02-20 | $9.62M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.17M derived: sum of 2 quarters · filed 2025-02-20 | $4.17M derived: sum of 3 quarters · filed 2025-02-20 | $4.17M 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |